Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Buy" by Brokerages

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has been assigned an average rating of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $17.29.

REPL has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their price objective on Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, September 24th. HC Wainwright restated a "buy" rating and issued a $17.00 price target on shares of Replimune Group in a report on Friday, November 22nd. Jefferies Financial Group boosted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets raised their target price on shares of Replimune Group from $14.00 to $18.00 and gave the company an "outperform" rating in a research note on Friday, November 22nd.

Replimune Group Stock Down 1.8 %

Shares of REPL traded down $0.22 during mid-day trading on Wednesday, hitting $12.11. The company's stock had a trading volume of 823,558 shares, compared to its average volume of 1,040,285. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The company's 50-day moving average is $12.41 and its 200-day moving average is $10.96. Replimune Group has a 52-week low of $4.92 and a 52-week high of $17.00. The firm has a market capitalization of $828.53 million, a price-to-earnings ratio of -3.97 and a beta of 1.26.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.07. On average, equities research analysts forecast that Replimune Group will post -2.91 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the firm's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company's stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Sushil Patel sold 10,000 shares of the company's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares in the company, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its position in Replimune Group by 3.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company's stock worth $2,733,000 after purchasing an additional 8,074 shares in the last quarter. Barclays PLC boosted its holdings in Replimune Group by 165.5% during the third quarter. Barclays PLC now owns 158,491 shares of the company's stock worth $1,738,000 after buying an additional 98,791 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Replimune Group by 17.9% during the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock worth $15,657,000 after buying an additional 217,308 shares in the last quarter. State Street Corp grew its position in Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock valued at $25,647,000 after buying an additional 1,182,181 shares during the period. Finally, Parkman Healthcare Partners LLC increased its holdings in Replimune Group by 45.5% in the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company's stock valued at $8,371,000 after buying an additional 238,747 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.